ArticleFrontiers in cell and developmental biology2025
Quantitation of global histone post-translational modifications reveal anti-inflammatory epigenetic mechanisms of liquiritigenin based on the optimized super-SILAC strategy.
Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Machine learning-driving optimization and spatial assembly of a cell-free system for high-yield liquiritigenin production.Advanced biotechnology · 2026Article
- H4K5 lactylation exacerbates acute myocarditis by driving a positive feedback loop between inflammation and metabolic dysfunction.Frontiers in immunology · 2026Article
- Harnessing Liquiritigenin: A Flavonoid-Based Approach for the Prevention and Treatment of Cancer.Cancers · 2025Review
- Editorial: Mechanism study of bioactive molecules using omics technology.Frontiers in cell and developmental biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liquiritigenin (LIQ) is a dihydroflavonone monomer compound with a planar ring structure that exhibits potent anti-inflammatory activity. The post-translational modifications (PTMs) of histones are closely associated with inflammatory diseases. To explore the relationships between the anti-inflammatory effects and epigenetic regulatory mechanisms of LIQ, we optimized the super stable isotope labeling by amino acids in cell culture (super-SILAC) method combined with a compound stimulation strategy. Moreover, we evaluated the identification coverage and demonstrated high reliability as well as reproducibility of the optimized method at both the peptide and cellular lysate levels, which are promising for elucidating disease pathology and drug mechanisms. We further applied the method to a system-wide characterization of histone PTMs in M1 macrophages treated with LIQ. The quantitative results showed that H4K5ac, H4K16ac, H3K9ac, H3K27ac, and H2BK12ac are significantly upregulated. Transcriptome analysis revealed that LIQ could exert anti-inflammatory effects by modulating the histone PTMs and regulating gene expressions through the peroxisome proliferator-activated receptor (PPAR) signaling pathway. Collectively, we provide a sensitive and universal strategy for research on the epigenetic mechanisms of natural products as well as facilitate epigenetic understanding of LIQ in inflammatory therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.